Clinical Trials | March 12, 2026
Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
Subscribe To Our Newsletter & Stay Updated
